Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemiaâ©.
Clin J Oncol Nurs
; 21(5): E248-E259, 2017 Oct 01.
Article
em En
| MEDLINE
| ID: mdl-28945721
ABSTRACT
BACKGROUND:
Acute lymphoblastic leukemia (ALL) is a common cancer in children, and outcomes have greatly improved because of the refinement of multiagent chemotherapy regimens that include intensified asparaginase therapy. Asparaginase, a cornerstone of modern pediatric chemotherapy regimens for ALL and asparaginase-containing protocols, is increasingly used in adolescent and adult patients historically treated with asparaginase-free regimens. â©.OBJECTIVES:
This article is an overview of commonly encountered asparaginase-associated toxicities and offers recommendations for treatment management.â©.METHODS:
A literature review was conducted, reviewing asparaginase and common toxicities, specifically hypersensitivity, pancreatitis, thrombosis, hyperbilirubinemia, and hyperglycemia.â©.FINDINGS:
The rapid identification and management of common asparaginase-associated adverse events can reduce symptom severity and limit potential interruptions to therapy, possibly improving outcomes.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Asparaginase
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
/
Guideline
/
Prognostic_studies
Limite:
Adolescent
/
Child
/
Child, preschool
/
Humans
/
Infant
Idioma:
En
Revista:
Clin J Oncol Nurs
Assunto da revista:
ENFERMAGEM
/
NEOPLASIAS
Ano de publicação:
2017
Tipo de documento:
Article